A new drug to treat the most common form of breast cancer has been shown in trials to reduce mortality by 29%.
The researchers presented their uplifting findings during a conference held by the American Society of Clinical Oncology in Chicago this weekend.
672 women, under the age of 59, with the most severe stage of cancer, participated in the study.
After 42 months of treatment, 70.2%of the women who received the new drug were still alive, compared to 46% of those who received placebo pills.
The drug Ribociclib, which is described as a cyclin inhibitor, is less poisonous than traditional chemotherapy, as it more selectively targets cancer cells and reduces their ability to spread.
© NTB Scanpix / #Norway Today
